Follow our progress

Publication highlights ensifentrine’s potential to provide rapid symptom relief LONDON and RALEIGH, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine

LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company

LONDON and RALEIGH, N.C., Aug. 26, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that, on August 20, 2020 it granted 6,794,521 Restricted American

New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that

Results expected in the first half of 2021 LONDON and RALEIGH, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of the second, multiple dose,

Completed $200 million private placement post period Phase 3 COPD clinical trials planned to start later this year Pilot clinical study in patients hospitalized with COVID-19 planned to start in the third quarter Conference Call Today at 9:00 am EDT / 2:00 pm BST LONDON and RALEIGH, N.C., Aug.

LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :

LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, notifies the following transactions by persons discharging managerial